Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma

Part of paid clinical trials in Columbus, Ohio.

Sponsor
Alpha Tau Medical LTD.
Study ID
NCT06910306
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • Device :DaRT seeds — DEVICE
    The sources are impregnated with a layer containing Ra-224 which is well fixated to the surface of the source. Ra-224 undergoes a series of decay events with each daughter product producing an alpha particle

Study Details

A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for the treatment of recurrent Glioblastoma

Key Dates

Start date
Oct 1, 2025
Status verified
Sep 2025
Primary completion
Nov 1, 2026
Completion
Dec 1, 2026

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental: DaRT seeds
    DaRT sources are inserted into the tumor according to a pre determined plan. The delivery of the DaRT Sources into the tumor is done by using a designated Alpha DaRT Applicator .

Primary Outcome Measure

Feasibility - DaRT seed placement [ Time Frame: From day 0 until 12 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Ohio State University Medical CenterColumbusOhio43210
Joshua Palmer, MD
[email protected]
917-601-3414

Find similar trials in Columbus, OH

By condition
Brain cancer
By specialty
OncologyNeuro-oncology
By research site
Ohio State University Medical Center· Columbus, OH

Related Studies